{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:05:31Z","timestamp":1793387131042,"version":"4.5.0"},"reference-count":115,"publisher":"American Medical Association (AMA)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2023,6,6]]},"abstract":"\n Importance<\/jats:title>\n \n Cystic fibrosis, a genetic disorder defined by variants in the cystic fibrosis transmembrane conductance regulator\n (CFTR)<\/jats:italic>\n gene, affects more than 30\u202f000 individuals in the US and approximately 89\u202f000 worldwide. Absent or decreased function of the CFTR protein is associated with multiorgan dysfunction and shortened life expectancy.\n <\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n CFTR is an anion channel in the apical membrane of epithelial cells. Loss of function leads to obstructed exocrine glands. Of people with cystic fibrosis in the US, approximately 85.5% have the gene variant F508del\n .<\/jats:italic>\n Manifestations of cystic fibrosis in patients with the F508del gene variant begin in infancy with steatorrhea, poor weight gain, and respiratory symptoms (coughing, wheezing). As people with cystic fibrosis age, chronic respiratory bacterial infections cause loss of lung function and bronchiectasis. With the availability of universal newborn screening in multiple countries including the US, many people with cystic fibrosis are asymptomatic at diagnosis. With multidisciplinary care teams that included dietitians, respiratory therapists, and social workers, treatment of cystic fibrosis can slow disease progression. Median survival has improved from 36.3 years (95% CI, 35.1-37.9) in 2006 to 53.1 years (95% CI, 51.6-54.7) in 2021. Pulmonary therapies for patients with cystic fibrosis consist of mucolytics (eg, dornase alfa), anti-inflammatories (eg, azithromycin), and antibiotics (such as tobramycin delivered by a nebulizer). Four small molecular therapies, termed\n CFTR modulators<\/jats:italic>\n , that facilitate CFTR production and\/or function have received regulatory approval. Examples are ivacaftor and elexacaftor-tezacaftor-ivacaftor. For example, in patients with 1 F508del variant, the combination of ivacaftor, tezacaftor, and elexacaftor improved lung function from \u22120.2% in the placebo group to 13.6% (difference, 13.8%; 95% CI, 12.1%-15.4%) and decreased the annualized estimated rate of pulmonary exacerbations from 0.98 to 0.37 (rate ratio, 0.37; 95% CI, 0.25-0.55). Improved respiratory function and symptoms have lasted up to 144 weeks in postapproval observational studies. An additional 177 variants are eligible for treatment with the elexacaftor-tezacaftor-ivacaftor combination.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Cystic fibrosis affects approximately 89\u202f000 people worldwide and is associated with a spectrum of disease related to exocrine dysfunction, including chronic respiratory bacterial infections and reduced life expectancy. First-line pulmonary therapies consist of mucolytics, anti-inflammatories, and antibiotics, and approximately 90% of people with cystic fibrosis who are 2 years or older may benefit from a combination of ivacaftor, tezacaftor, and elexacaftor.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2023.8120","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T13:09:42Z","timestamp":1686056982000},"page":"1859","source":"Crossref","is-referenced-by-count":338,"title":["Cystic Fibrosis"],"prefix":"10.1001","volume":"329","author":[{"given":"Thida","family":"Ong","sequence":"first","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle Children\u2019s Hospital, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle Children\u2019s Hospital, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"jrv230011r2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective.","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"jrv230011r4","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion channel modulators in cystic fibrosis.","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"issue":"2","key":"jrv230011r5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"10290","key":"jrv230011r7","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis.","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"jrv230011r8","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union.","volume":"7","author":"Farrell","year":"2008","journal-title":"J Cyst Fibros"},{"issue":"8","key":"jrv230011r9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/resp.12656","article-title":"Epidemiology and genetics of cystic fibrosis in Asia: in preparation for the next-generation treatments.","volume":"20","author":"Singh","year":"2015","journal-title":"Respirology"},{"issue":"3","key":"jrv230011r10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jcf.2006.07.004","article-title":"CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent.","volume":"6","author":"P\u00e9rez","year":"2007","journal-title":"J Cyst Fibros"},{"issue":"4","key":"jrv230011r11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease.","volume":"372","author":"Stoltz","year":"2015","journal-title":"N Engl J Med"},{"issue":"181","key":"jrv230011r12","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation.","volume":"181S","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"1","key":"jrv230011r13","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.97199","article-title":"Development of an airway mucus defect in the cystic fibrosis rat.","volume":"3","author":"Birket","year":"2018","journal-title":"JCI Insight"},{"key":"jrv230011r14","first-page":"241","article-title":"Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases.","volume":"2","author":"Oppenheimer","year":"1975","journal-title":"Perspect Pediatr Pathol"},{"issue":"3","key":"jrv230011r15","first-page":"303","article-title":"Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants.","volume":"106","author":"Sturgess","year":"1982","journal-title":"Am J Pathol"},{"issue":"21","key":"jrv230011r16","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1301725","article-title":"Risk factors for bronchiectasis in children with cystic fibrosis.","volume":"368","author":"Sly","year":"2013","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv230011r17","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jpeds.2009.05.005","article-title":"Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening.","volume":"155","author":"Stick","year":"2009","journal-title":"J Pediatr"},{"issue":"485","key":"jrv230011r18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis.","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"jrv230011r19","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"issue":"7","key":"jrv230011r20","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","article-title":"Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis.","volume":"73","author":"Welsh","year":"1993","journal-title":"Cell"},{"issue":"10","key":"jrv230011r21","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1164\/rccm.201910-1943SO","article-title":"Cystic fibrosis: emergence of highly effective targeted therapeutics and potential clinical implications.","volume":"201","author":"Mall","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"10212","key":"jrv230011r22","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"jrv230011r23","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele.","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"21","key":"jrv230011r24","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1001\/jama.2017.16823","article-title":"Treating specific variants causing cystic fibrosis.","volume":"318","author":"Cutting","year":"2017","journal-title":"JAMA"},{"key":"jrv230011r25","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in cystic fibrosis.","volume":"16","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"12","key":"jrv230011r26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1164\/rccm.201606-1107CI","article-title":"Early lung disease in infants and preschool children with cystic fibrosis: what have we learned and what should we do about it?","volume":"195","author":"Ranganathan","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv230011r27","first-page":"522","article-title":"Cystic fibrosis pulmonary guidelines: airway clearance therapies.","volume":"54","author":"Flume","year":"2009","journal-title":"Respir Care"},{"issue":"1","key":"jrv230011r28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011231.pub2","article-title":"Airway clearance techniques for cystic fibrosis: an overview of Cochrane systematic reviews.","volume":"1","author":"Wilson","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"jrv230011r29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv230011r30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision.","volume":"17","author":"Castellani","year":"2018","journal-title":"J Cyst Fibros"},{"issue":"3","key":"jrv230011r31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub5","article-title":"Dornase alfa for cystic fibrosis.","volume":"3","author":"Yang","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv230011r32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001127.pub5","article-title":"Nebulised hypertonic saline for cystic fibrosis.","volume":"9","author":"Wark","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"jrv230011r33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S2213-2600(19)30187-0","article-title":"Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"7","author":"Ratjen","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"10","key":"jrv230011r34","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1164\/rccm.201807-1203OC","article-title":"Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). a randomized, double-blind, controlled study.","volume":"199","author":"Stahl","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"jrv230011r35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008649.pub4","article-title":"Inhaled mannitol for cystic fibrosis.","volume":"5","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"jrv230011r36","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jcf.2021.02.011","article-title":"Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: an international, randomized controlled study.","volume":"20","author":"Flume","year":"2021","journal-title":"J Cyst Fibros"},{"key":"jrv230011r37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The immunomodulatory effects of macrolides\u2014a systematic review of the underlying mechanisms.","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"jrv230011r38","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203.pub4","article-title":"Macrolide antibiotics for cystic fibrosis.","volume":"11","author":"Southern","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"jrv230011r39","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-2600(22)00165-5","article-title":"The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial.","volume":"10","author":"Stick","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"9","key":"jrv230011r40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001505.pub5","article-title":"Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis.","volume":"9","author":"Lands","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"jrv230011r41","first-page":"761","article-title":"Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum.","volume":"132","author":"Mendelman","year":"1985","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"jrv230011r42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001021.pub4","article-title":"Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.","volume":"3","author":"Smith","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"jrv230011r43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus.","volume":"8","author":"Heijerman","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"9","key":"jrv230011r44","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations.","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv230011r45","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis.","volume":"40","author":"Goss","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"4 pt 1","key":"jrv230011r46","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1164\/ajrccm\/141.4_Pt_1.914","article-title":"Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.","volume":"141","author":"Regelmann","year":"1990","journal-title":"Am Rev Respir Dis"},{"issue":"11","key":"jrv230011r47","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment.","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv230011r48","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation.","volume":"21","author":"Sanders","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"jrv230011r49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease.","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"8","key":"jrv230011r50","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.v23.8","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents.","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"jrv230011r51","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jcf.2021.07.014","article-title":"The impact of liver disease on mortality in cystic fibrosis\u2014a systematic review.","volume":"21","author":"Sasame","year":"2022","journal-title":"J Cyst Fibros"},{"key":"jrv230011r52","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1016\/j.jcf.2019.08.017","article-title":"Cystic fibrosis bone disease treatment: current knowledge and future directions.","volume":"18","author":"Putman","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"21","key":"jrv230011r53","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis.","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"issue":"1-2","key":"jrv230011r54","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgme.2021.08.005","article-title":"Improving outcomes for Colorado\u2019s IRT-IRT-DNA cystic fibrosis newborn screening algorithm by implementing floating cutoffs.","volume":"134","author":"Martiniano","year":"2021","journal-title":"Mol Genet Metab"},{"issue":"3","key":"jrv230011r55","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ppul.v58.3","article-title":"Variation in cystic fibrosis newborn screening algorithms in the United States.","volume":"58","author":"Rehani","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"jrv230011r56","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/ppul.v54.3","article-title":"Comparison of two sweat test systems for the diagnosis of cystic fibrosis in newborns.","volume":"54","author":"Rueegg","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"181","key":"jrv230011r57","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jpeds.2016.09.066","article-title":"Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis.","volume":"181S","author":"Ren","year":"2017","journal-title":"J Pediatr"},{"issue":"5","key":"jrv230011r58","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcf.2020.11.006","article-title":"Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome\/cystic fibrosis screen positive, inconclusive diagnosis (CRMS\/CFSPID).","volume":"20","author":"Barben","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"11","key":"jrv230011r59","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/thx.2003.020933","article-title":"Nasal airway ion transport is linked to the cystic fibrosis phenotype in adult patients.","volume":"59","author":"Fajac","year":"2004","journal-title":"Thorax"},{"key":"jrv230011r60","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.jcf.2014.03.009","article-title":"European Cystic Fibrosis Society Standards of Care: framework for the Cystic Fibrosis Centre.","volume":"13","author":"Conway","year":"2014","journal-title":"J Cyst Fibros"},{"issue":"6","key":"jrv230011r61","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jpeds.2009.09.001","article-title":"Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.","volume":"155","author":"Borowitz","year":"2009","journal-title":"J Pediatr"},{"issue":"1","key":"jrv230011r62","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety.","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"issue":"3","key":"jrv230011r63","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.gastro.2017.12.012","article-title":"Cystic fibrosis colorectal cancer screening consensus recommendations.","volume":"154","author":"Hadjiliadis","year":"2018","journal-title":"Gastroenterology"},{"issue":"10","key":"jrv230011r64","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv230011r65","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis.","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"jrv230011r66","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"18","key":"jrv230011r68","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv230011r69","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"jrv230011r70","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"jrv230011r71","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in infants aged 4 to <12 months with cystic fibrosis and a gating mutation. results of a two-part phase 3 clinical trial.","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv230011r73","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR.","volume":"373","author":"Wainwright","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv230011r74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"2","key":"jrv230011r75","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"21","key":"jrv230011r77","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del.","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv230011r79","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes.","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv230011r80","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1164\/rccm.202202-0392OC","article-title":"Efficacy and safety of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3b, randomized, placebo-controlled study.","volume":"206","author":"Mall","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv230011r81","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","article-title":"Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis.","volume":"128","author":"Quittner","year":"2005","journal-title":"Chest"},{"issue":"3","key":"jrv230011r82","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1378\/chest.11-2672","article-title":"Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation.","volume":"142","author":"Flume","year":"2012","journal-title":"Chest"},{"issue":"9","key":"jrv230011r83","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"7","key":"jrv230011r84","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","article-title":"Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.","volume":"9","author":"Chilvers","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"jrv230011r85","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1164\/rccm.201704-0717OC","article-title":"Tezacaftor\/ivacaftor in subjects with cystic fibrosis and F508del\/F508del-CFTR or F508del\/G551D-CFTR.","volume":"197","author":"Donaldson","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"jrv230011r86","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S2213-2600(14)70132-8","article-title":"A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.","volume":"2","author":"Boyle","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"18","key":"jrv230011r87","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"issue":"17","key":"jrv230011r88","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles.","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"jrv230011r89","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/S1569-1993(22)00861-X","article-title":"Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study.","volume":"21","author":"Griese","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"12","key":"jrv230011r90","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele.","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"jrv230011r91","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2 through 5 years with cystic fibrosis and at least one F508del allele.","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv230011r92","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions.","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"4","key":"jrv230011r93","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"jrv230011r94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review.","volume":"10","author":"Dagenais","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"jrv230011r95","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/genes11060589","article-title":"The changing epidemiology of cystic fibrosis: incidence, survival and impact of the CFTR gene discovery.","volume":"11","author":"Scotet","year":"2020","journal-title":"Genes (Basel)"},{"issue":"6","key":"jrv230011r96","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1001\/jamapediatrics.2017.0206","article-title":"Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life.","volume":"171","author":"Leung","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"10","key":"jrv230011r97","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamapediatrics.2022.2674","article-title":"Real-world associations of US cystic fibrosis newborn screening programs with nutritional and pulmonary outcomes.","volume":"176","author":"Rosenfeld","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"1","key":"jrv230011r98","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries.","volume":"19","author":"Volkova","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"5","key":"jrv230011r99","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial.","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv230011r100","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease.","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv230011r101","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1378\/chest.14-2189","article-title":"Assessing differences in mortality rates and risk factors between Hispanic and non-Hispanic patients with cystic fibrosis in California.","volume":"149","author":"Buu","year":"2016","journal-title":"Chest"},{"issue":"1","key":"jrv230011r102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jcf.2022.07.010","article-title":"Disparities in first evaluation of infants with cystic fibrosis since implementation of newborn screening.","volume":"22","author":"McColley","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"2","key":"jrv230011r103","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/ppul.v58.2","article-title":"Detection of disease-causing CFTR variants in state newborn screening programs.","volume":"58","author":"McGarry","year":"2023","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"jrv230011r104","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/ppul.v56.6","article-title":"Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.","volume":"56","author":"McGarry","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"jrv230011r105","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials.","author":"Mayer-Hamblett","year":"2022","journal-title":"Lancet Respir Med"},{"key":"jrv230011r107","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1163391","article-title":"Real-world disparities and ethical considerations with access to CFTR modulator drugs: mind the gap!","volume":"14","author":"Zampoli","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"jrv230011r108","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001289","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"jrv230011r109","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3390\/nu14061216","article-title":"The changing landscape of nutrition in cystic fibrosis: the emergence of overweight and obesity.","volume":"14","author":"Bailey","year":"2022","journal-title":"Nutrients"},{"issue":"3","key":"jrv230011r110","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jcf.2021.07.019","article-title":"Pregnancy in cystic fibrosis: review of the literature and expert recommendations.","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"1","key":"jrv230011r111","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jcf.2020.07.020","article-title":"Decreased survival in cystic fibrosis patients with a positive screen for depression.","volume":"20","author":"Schechter","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"12","key":"jrv230011r112","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries.","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"4","key":"jrv230011r113","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ccm.2022.06.011","article-title":"Non-modulator therapies: developing a therapy for every cystic fibrosis patient.","volume":"43","author":"Egan","year":"2022","journal-title":"Clin Chest Med"},{"issue":"R1","key":"jrv230011r114","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1093\/hmg\/ddz139","article-title":"Advances in gene therapy for cystic fibrosis lung disease.","volume":"28","author":"Yan","year":"2019","journal-title":"Hum Mol Genet"},{"issue":"6","key":"jrv230011r115","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.stem.2013.11.002","article-title":"Functional repair of CFTR by CRISPR\/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.","volume":"13","author":"Schwank","year":"2013","journal-title":"Cell Stem Cell"},{"key":"jrv230011r1","unstructured":"Cystic Fibrosis Foundation. National Patient Registry 2021: Annual Data Report. 2023. Accessed April 23, 2023. https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/Patient-Registry-Annual-Data-Report.pdf"},{"key":"jrv230011r3","unstructured":"Cystic fibrosis mutation database (CFTR1). Updated April 7, 2023. Accessed April 23, 2023. http:\/\/www.genet.sickkids.on.ca\/"},{"key":"jrv230011r6","unstructured":"The clinical and functional translation of CFTR (CFTR2). Cystic Fibrosis Foundation, Johns Hopkins Medicine, and Sequenom Laboratories. Accessed April 23, 2023. http:\/\/cftr2.org"},{"key":"jrv230011r67","unstructured":"Ivacaftor prescribing information. Vertex Pharmaceuticals Inc. Accessed April 23, 2023. https:\/\/pi.vrtx.com\/files\/uspi_ivacaftor.pdf"},{"key":"jrv230011r72","unstructured":"Lumacaftor-ivacaftor prescribing information. Vertex Pharmaceuticals Inc. Accessed April 23, 2023. https:\/\/pi.vrtx.com\/files\/uspi_lumacaftor_ivacaftor.pdf"},{"key":"jrv230011r76","unstructured":"Tezacaftor-ivacaftor prescribing information. Vertex Pharmaceuticals Inc. Accessed April 23, 2023. https:\/\/pi.vrtx.com\/files\/uspi_tezacaftor_ivacaftor.pdf"},{"key":"jrv230011r78","unstructured":"Elexacaftor-tezacaftor-ivacaftor prescribing information. Vertex Pharmaceuticals Inc. Accessed April 23, 2023. https:\/\/pi.vrtx.com\/files\/uspi_elexacaftor_tezacaftor_ivacaftor.pdf"},{"key":"jrv230011r106","unstructured":"Tice? JA, Kuntz? KM, Wherry? K, . Modulator treatments for cystic fibrosis: effectiveness and value: final evidence report and meeting summary. Institute of Economic Review. September 23, 2020. Accessed April 23, 2023. https:\/\/icer.org\/wp-content\/uploads\/2020\/08\/ICER_CF_Final_Report_092320.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2805701\/jama_ong_2023_rv_230011_1685658841.68933.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T13:09:50Z","timestamp":1686056990000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2805701"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":115,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,6,6]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2023.8120","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,6]]}}}